SCHEMBL1371196

SCHEMBL1371196

CCc1ccc(-c2[c]cccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.44
CYP2A6 P11509 2/20 0.36
CYP1A2 P05177 1/20 0.36
EGFR P00533 1/20 0.36
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
KDM4E B2RXH2 1/20 0.35
NOTUM Q6P988 1/20 0.35
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
METAP2 P50579 1/20 0.34
KCNH2 Q12809 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
MGLL Q99685 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
LPL P06858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368894 0.85 LPL (0.37) NPC1RAB9AKDM4EKCNH2SMN1; SMN2
SCHEMBL1370764 0.82 HSD11B1 (0.47) TP53NPC1RAB9AKDM4ECTSV
SCHEMBL2228477 0.80 HRH3 (0.58) KDM4ETAAR1MAPK1L3MBTL1
SCHEMBL8081767 0.80 HSD11B1 (0.49) TP53EGFRRAB9AKDM4EKCNH2
SCHEMBL1775198 0.80 TRPA1 (0.44) TAAR1ALDH1A1
SCHEMBL9029706 0.80 TAAR1 (0.54) TP53CYP2A6NPC1KDM4ETAAR1
SCHEMBL6609575 0.80 TSHR (0.44) LMNA
SCHEMBL3639347 0.79 BCL2 (0.42) TP53CYP2A6CYP1A2NPC1RAB9A
SCHEMBL3742259 0.79 MEN1 (0.39) CYP2A6TAAR1NFKB1MAPTLMNA
Ethylamine SCHEMBL27831005 0.78 TAAR1 (0.35) TP53CYP2A6NPC1RAB9ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6888022-B2 Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis ATHENA NEUROSCIENCES, INC. (US) 2005-05-03 US claimed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP claimed
US-20030229024-A1 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis AUDIA JAMES E (US) 2003-12-11 US claimed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO claimed
US-20020052322-A1 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis ELAN PHARMACEUTICALS, INC. 2002-05-02 US claimed
US-6191166-B1 ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2001-02-20 US claimed
CN-1238779-A Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis ELAN PHARM INC (US) 1999-12-15 CN claimed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP claimed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO claimed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO claimed
CN-116034147-B Adhesive composition containing antistatic agent and surface protective film 株式会社LG化学 2024-04-05 CN disclosed
US-20230323171-A1 ADHESIVE COMPOSITION CONTAINING ANTISTATIC AGENT AND SURFACE PROTECTIVE FILM XINMEI FONTANA HOLDING (HONG KONG) LIMITED (CN) 2023-10-12 US disclosed
EP-4190877-A1 ADHESIVE COMPOSITION CONTAINING ANTISTATIC AGENT AND SURFACE PROTECTIVE FILM Lg Chem, Ltd. (KR) 2023-06-07 EP disclosed
CN-116034147-A Adhesive composition containing antistatic agent and surface protective film 株式会社LG化学 2023-04-28 CN disclosed
CN-112996876-B Adhesive composition, surface protective film, and method for manufacturing organic light-emitting electronic device 株式会社LG化学 2023-04-18 CN disclosed
EP-0707585-A1 BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES PFIZER INC. (US) 1996-04-24 EP disclosed
WO-1995001980-A1 BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES PFIZER INC. (US) 1995-01-19 WO disclosed
EP-0407877-A2 1,2-Dihaloazolylethane derivatives and fungicides containing them BASF Aktiengesellschaft (DE) 1991-01-16 EP disclosed
US-4524168-A AZO DYES CIBA-GEIGY CORPORATION (US) 1985-06-18 US disclosed
EP-0001937-B1 PROCESS FOR THE HYDROCARBONYLATION OF METHANOL TO ETHANOL IN THE PRESENCE OF AN INERT LIQUID The British Petroleum Company p.l.c. (GB) 1981-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052322-A1 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis APP, BACE1, IAPP TP53 1452/4885CYP2A6 3470/4885CYP1A2 4192/4885
US-20030229024-A1 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis APP, BACE1, IAPP TP53 1452/4885CYP2A6 3470/4885CYP1A2 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.